HOME >> BIOLOGY >> NEWS
Clinical trial shows timing of chemotherapy improves survival in breast cancer

New York, December 12, 2002 New research shows that giving doses of chemotherapy more frequently in time, leads to a significant improvement in survival with no increase in toxicity in women with node-positive breast cancer. The study, coordinated by the Cancer and Leukemia Group B (CALGB) for the National Cancer Institute's Breast Intergroup, found a 31 percent decrease in the death rate with more frequent chemotherapy administration, called "dose dense," compared to conventional treatment. The findings will be presented today at the 25th Annual San Antonio Breast Cancer Symposium.

"Since breast cancer is so common, and adjuvant drug therapy has already been found to be so effective, a way to make that treatment 31 percent more effective could potentially save thousands of lives per year in the United States alone," said Larry Norton, MD, Head of the Division of Solid Tumor Oncology at Memorial Sloan-Kettering Cancer Center, and senior author of the study.

A mathematical model called the Norton-Simon hypothesis formed the basis for the concept of dose density and another concept tested in this study, sequential therapy. The model, developed by Dr. Norton, and Richard Simon of the National Cancer Institute, was used to address the question: "Is it better to use a higher dose of a drug less often or a lower dose more frequently?" According to Dr. Norton, the answer depended upon the efficacy of the drugs and the pattern of growth of the disease, and could not be answered without a mathematical understanding of the underlying biology.

The study enrolled 2005 women with primary breast cancer that had spread to the lymph nodes, and with no other metastases. They were randomized post-operatively to one of four treatments. Two groups of patients were randomized to receive doxorubicin (A for Adriamycin), paclitaxel (T for Taxol), and cyclophosphamide (C for Cytoxan) sequentially, i.e., one at a time, in two- or three-week c
'"/>

Contact: Christine Hickey
media@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
12-Dec-2002


Page: 1 2 3

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study reports findings of combination therapy with DOXIL
9. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
(Date:10/31/2014)... letting the air out of a nagging mystery about the ... speculated as to why animal species didn,t flourish sooner, once ... at the end of the Proterozoic period, about 800 million ... that, when most researchers think there also was plenty of ... then, after all. , In a study published Oct. 30 ...
(Date:10/31/2014)... is good for attracting species, but it may not be ... Iowa study has found. , The researchers surveyed two types ... the abundance of two insects that interact with them. They ... cherry and black walnut, they didn,t find a corresponding abundance ... on the walnuts and black cherries and a type of ...
(Date:10/31/2014)... programmed cell death, offering new targets for the treatment ... , The research teams from the Walter and Eliza ... of a key cell death protein called Bak and ... death. Their studies were published in Molecular ... National Academy of Sciences . , Programmed ...
Breaking Biology News(10 mins):Lack of oxygen delayed the rise of animals on Earth 2Green spaces don't ensure biodiversity in urban areas 2A matter of life and death: Cell death proteins key to fighting disease 2
(Date:10/31/2014)... October 31, 2014 Stronger investment ... construction, finance and consumer electronics will help fuel ... industry research firm IBISWorld has added a report ... growing industry report collection. , The Biometrics Scan ... biometric technologies such as fingerprint, iris, retina and ...
(Date:10/31/2014)... 31, 2014  Atlanta-based Intellimedix could make a ... onset of Ebola by suggesting a new, computational ... Tech,s Center for Computational Systems Biology have spent ... alternative uses for existing drugs through systematic repurposing, ... the bout against Ebola. Logo ...
(Date:10/30/2014)... LONDON , October 30, 2014 ... Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... PCYC ), Synthetic Biologics Inc. (NYSE MKT: SYN), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,549.23, down 0.33%, the Dow Jones ...
(Date:10/30/2014)... Global polyvinyl chloride (PVC) demand registered ... during 2008-2009, especially in North America and Europe. However, ... keeping to a growing trend. , The largest chunk ... the construction segment. In 2013, the key PVC application ... and rigid film. Moreover, the PVC was consumed in ...
Breaking Biology Technology:Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Atlanta-Based Intellimedix May Help Solve Ebola With Computer Algorithms 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3
Cached News: